BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 17519543)

  • 1. Variable platelet response to aspirin in patients with ischemic stroke.
    Hohlfeld T; Weber AA; Junghans U; Schumacher M; Boucher M; Schrör K; Siebler M
    Cerebrovasc Dis; 2007; 24(1):43-50. PubMed ID: 17519543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke.
    Karepov V; Tolpina G; Kuliczkowski W; Serebruany V
    Cerebrovasc Dis; 2008; 26(3):272-6. PubMed ID: 18648200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke].
    Oláh L; Misz M; Bereczki D; Fekete I; Bordánné JE; Takács EI
    Orv Hetil; 1996 Mar; 137(9):455-9. PubMed ID: 8714038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans.
    Anger K; Kempfert J; Kostelka M; Mohr FW; Dhein S
    Pharmacology; 2010; 85(4):241-7. PubMed ID: 20332671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.
    Schwammenthal Y; Tsabari R; Shenkman B; Schwartz R; Matetzky S; Lubetsky A; Orion D; Israeli-Korn S; Chapman J; Savion N; Varon D; Tanne D
    Cerebrovasc Dis; 2008; 25(4):355-61. PubMed ID: 18305387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
    Pongrácz E
    Clin Hemorheol Microcirc; 2004; 30(3-4):237-42. PubMed ID: 15258349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
    Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
    Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction.
    Valles J; Santos MT; Fuset MP; Moscardo A; Ruano M; Perez F; Piñon M; Breña S; Aznar J
    Am J Cardiol; 2007 Jan; 99(1):19-25. PubMed ID: 17196455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease (IHD) as bioindicator of the treatment strategy].
    Malý J; Pecka M; Gregor J; Dulícek P; Blazek M; Malý R; Pudil R; Bláha M
    Cas Lek Cesk; 2005; 144 Suppl 3():23-9. PubMed ID: 16335259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
    Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
    Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can aspirin resistance be clinically predicted in stroke patients?
    Seok JI; Joo IS; Yoon JH; Choi YJ; Lee PH; Huh K; Bang OY
    Clin Neurol Neurosurg; 2008 Feb; 110(2):110-6. PubMed ID: 17964711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
    Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
    Gengo FM; Rainka M; Robson M; Gengo MF; Forrest A; Hourihane M; Bates V
    J Clin Pharmacol; 2008 Mar; 48(3):335-43. PubMed ID: 18223144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
    Smout J; Cleanthis M; Stansby G
    Thromb Haemost; 2008 Jan; 99(1):239. PubMed ID: 18217162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 51.